- Record: found
- Abstract: not found
- Article: not found
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R Lyon
1 ,
Teresa López-Fernández
2 ,
Liam S Couch
1 ,
Riccardo Asteggiano
3 ,
Marianne C Aznar
1 ,
Jutta Bergler-Klein
4 ,
Giuseppe Boriani
3 ,
Daniela Cardinale
3 ,
Raul Cordoba
2 ,
Bernard Cosyns
5 ,
David J Cutter
1 ,
Evandro de Azambuja
5 ,
Rudolf A de Boer
6 ,
Susan F Dent
7 ,
Dimitrios Farmakis
8 ,
Sofie A Gevaert
5 ,
Diana A Gorog
1 ,
Joerg Herrmann
7 ,
Daniel Lenihan
7 ,
Javid Moslehi
7 ,
Brenda Moura
9 ,
Sonja S Salinger
10 ,
Richard Stephens
1 ,
Thomas M Suter
11 ,
Sebastian Szmit
12 ,
Juan Tamargo
2 ,
Paaladinesh Thavendiranathan
13 ,
Carlo G Tocchetti
3 ,
Peter van der Meer
6 ,
Helena J H van der Pal
6
Nov 01 2022
Amyloid light-chain cardiac amyloidosis,
Androgen deprivation therapy,
Anthracycline,
Arrhythmias,
Atrial fibrillation,
Biomarkers,
Cancer,
Cancer survivors,
Carcinoid syndrome,
Cardiac magnetic resonance,
Cardiac tumour,
Cardio-oncology,
Cardiotoxicity,
Chemotherapy,
Coronary artery disease,
Echocardiography,
Fluoropyrimidine,
Guidelines,
Haematopoietic stem cell transplantation,
Heart failure,
Hormone therapy,
Hypertension,
Immunotherapy,
Ischaemic heart disease,
Myocarditis,
Pericardial disease,
Proteasome inhibitors,
Pulmonary hypertension,
QTc prolongation,
Radiotherapy,
Risk stratification,
Strain,
Thrombosis,
Trastuzumab,
Valvular heart disease,
Vascular endothelial growth factor inhibitors (VEGFi),
Venous thromboembolism
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
Proteasome inhibitors,Pericardial disease,Myocarditis,Ischaemic heart disease,Immunotherapy,Hypertension,Hormone therapy,Heart failure,Haematopoietic stem cell transplantation,Guidelines,Fluoropyrimidine,Echocardiography,Coronary artery disease,Venous thromboembolism,Cardiotoxicity,Cardio-oncology,Cardiac tumour,Cardiac magnetic resonance,Carcinoid syndrome,Cancer survivors,Cancer,Biomarkers,Atrial fibrillation,Arrhythmias,Anthracycline,Androgen deprivation therapy,Amyloid light-chain cardiac amyloidosis,Chemotherapy,Vascular endothelial growth factor inhibitors (VEGFi),Valvular heart disease,Trastuzumab,Thrombosis,Strain,Risk stratification,Radiotherapy,QTc prolongation,Pulmonary hypertension
Proteasome inhibitors, Pericardial disease, Myocarditis, Ischaemic heart disease, Immunotherapy, Hypertension, Hormone therapy, Heart failure, Haematopoietic stem cell transplantation, Guidelines, Fluoropyrimidine, Echocardiography, Coronary artery disease, Venous thromboembolism, Cardiotoxicity, Cardio-oncology, Cardiac tumour, Cardiac magnetic resonance, Carcinoid syndrome, Cancer survivors, Cancer, Biomarkers, Atrial fibrillation, Arrhythmias, Anthracycline, Androgen deprivation therapy, Amyloid light-chain cardiac amyloidosis, Chemotherapy, Vascular endothelial growth factor inhibitors (VEGFi), Valvular heart disease, Trastuzumab, Thrombosis, Strain, Risk stratification, Radiotherapy, QTc prolongation, Pulmonary hypertension